18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis
Cancer Chemotherapy and Pharmacology, ISSN: 1432-0843, Vol: 93, Issue: 6, Page: 575-585
2024
- 2Citations
- 2Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- Captures2
- Readers2
- Mentions1
- News Mentions1
- 1
Most Recent News
GA-LDV: A Promising Derivative of 18β-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
Introduction Malignant tumors pose a significant threat to human health, with approximately 90% of cancer-related mortalities attributed to tumor metastasis.1,2 Tumor metastasis is a multistep
Article Description
Purpose: 18β-glycyrrhetinic acid (GA), the main metabolite of glycyrrhizic acid extracted from the root of licorice, has been reported to possess anti-cancer and immunomodulatory activity, but the mechanisms are not well understood. Recent studies have shown that ferroptosis of immune cells is involved in tumor-associated immune suppression. The purpose of this study was to investigate whether the enhanced immune response via inhibiting immune cell ferroptosis contributed to the anticancer effect of 18β-GA. Methods: Lewis Lung carcinoma mouse model and Murine CD8 + T cell culture model were used to examine the changes of immune response and ferroptosis of immune cells. Results: We found that 18β-GA was effective against lung cancer accompanied by enhanced activation of tumor-infiltrating CD8 T cells in Lewis Lung carcinoma mouse model. Furthermore, we demonstrated that the boosted immune response by GA was attributed to its ability to inhibit arachidonic acid (AA)-mediated CD8 T ferroptosis via suppressing CD36 expression. Conclusion: The findings of the present study unraveled a novel mechanism underlying the anti-cancer and immunomodulatory activity of 18β-GA and support that 18β-GA holds potential to be used as an immune enhancer for lung cancer prevention or treatment.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185449694&origin=inward; http://dx.doi.org/10.1007/s00280-024-04639-7; http://www.ncbi.nlm.nih.gov/pubmed/38383823; https://link.springer.com/10.1007/s00280-024-04639-7; https://dx.doi.org/10.1007/s00280-024-04639-7; https://link.springer.com/article/10.1007/s00280-024-04639-7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know